OR WAIT null SECS
Recipharm announced that it has invested 5 million SEK in a new GLP bioanalysis laboratory in Uppsala.
On Oct. 17, 2016, Recipharm announced a 5-million SEK (approximately $566,546.50) investment in a new GLP compliant bioanalysis laboratory at its development facility in Uppsala, Sweden, in response to growing customer demand. The 500-square-meter facility is expected to open in November 2016. According to Recipharm, this facility will become the largest GLP bioanalysis laboratory of its kind in the Nordic countries.
Recipharm’s development team in Uppsala specializes in medicinal chemistry, offering synthesis and analytical preclinical development services to drug-development companies progressing products through clinical trials. This new laboratory will allow Recipharm to increase its capacity, with the capability to process more than 10,000 plasma samples per week. In order to support the increasing demand of bioanalysis services, Recipharm Development in Uppsala plans to recruit several new PhD-level chemists in the coming months and aims to more than double its team of 35 in the next couple of years.
“This is a strategic investment for Recipharm as there is a real need for more GLP bioanalysis laboratories in the Nordic region,” Fredrik Lehmann, general manager of Recipharm Development in Uppsala said in a statement. “Bioanalysis requires specialist expertise and establishing the necessary capabilities can be a costly investment, proving a barrier to entry for many contract services providers. Having first started out in a collaboration with a subcontractor, we are now delighted to be able to expand our offering in-house to service an unmet need for bioanalysis capabilities.”